Catatan sumber primer
PenentuHasil topline
Annexon: Data topline Fase 3 ARCHER II untuk vonaprument pada GA diperkirakan Q4 2026
Perusahaan mengumumkan bahwa data pivotal Fase 3 topline dari uji coba ARCHER II untuk vonaprument pada geographic atrophy kini diperkirakan pada Q4 2026. Pembacaan ini merupakan tonggak klinis/regulasi utama berikutnya untuk aset tersebut dan dimaksudkan untuk mendukung registrasi global.
Fakta utama
- Diajukan
- 7 Mei 2026, 20.05
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
ANNXAnnexon- Aset
- vonaprument
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 annx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré Syndrome (GBS); Biologics License Application (BLA) Submission with U.S./European FORWARD Data Expected in 2026 Proof-of-Concept (POC) Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $225 Million as of M